<code id='BC1A8B0D5C'></code><style id='BC1A8B0D5C'></style>
    • <acronym id='BC1A8B0D5C'></acronym>
      <center id='BC1A8B0D5C'><center id='BC1A8B0D5C'><tfoot id='BC1A8B0D5C'></tfoot></center><abbr id='BC1A8B0D5C'><dir id='BC1A8B0D5C'><tfoot id='BC1A8B0D5C'></tfoot><noframes id='BC1A8B0D5C'>

    • <optgroup id='BC1A8B0D5C'><strike id='BC1A8B0D5C'><sup id='BC1A8B0D5C'></sup></strike><code id='BC1A8B0D5C'></code></optgroup>
        1. <b id='BC1A8B0D5C'><label id='BC1A8B0D5C'><select id='BC1A8B0D5C'><dt id='BC1A8B0D5C'><span id='BC1A8B0D5C'></span></dt></select></label></b><u id='BC1A8B0D5C'></u>
          <i id='BC1A8B0D5C'><strike id='BC1A8B0D5C'><tt id='BC1A8B0D5C'><pre id='BC1A8B0D5C'></pre></tt></strike></i>

          knowledge

          knowledge

          author:knowledge    Page View:151
          The Amgen booth at ESMO in Madrid.
          The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

          MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

          The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

          advertisement

          “It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Why Novartis is changing the name of its research labs
          Why Novartis is changing the name of its research labs

          FionaMarshall,presidentoftheNovartisresearchhubinCambridge,Mass.,speaksThursdayduringtheSTATFutureSu

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Snackable artificial intelligence, expert AI, and the pharma industry

          AdobeWhileit’swidelyacceptedthatthepharmaindustryisinnovativeinR&D,itisalsotruethatitcanbeslowat